UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 169

Sortiert nach

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Arthritis & rheumatology (Hoboken, N.J.), 2018-01, Vol.70 (1), p.60-68

2018

Link zum Volltext

Verfügbarkeit prüfen

The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.998-1003

2015

Link zum Volltext

Verfügbarkeit prüfen

Non‐Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.810-814

2023

Link zum Volltext

Verfügbarkeit prüfen

i033 Biologic dose reduction: the physician's perspective

Rheumatology (Oxford, England), 2018-04, Vol.57 (suppl_3)

Broeder, Alfons Den

2018

Link zum Volltext

Verfügbarkeit prüfen

Genome‐wide Association Study of Methotrexate‐Induced Liver Injury in Rheumatoid Arthritis Patients

Clinical pharmacology and therapeutics, 2023-04, Vol.113 (4), p.916-923

2023

Link zum Volltext

Verfügbarkeit prüfen

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

Annals of the rheumatic diseases, 2012-06, Vol.71 (6), p.845-850

2012

Link zum Volltext

Verfügbarkeit prüfen

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study

Annals of the rheumatic diseases, 2017-10, Vol.76 (10), p.1693

2017

Link zum Volltext

Verfügbarkeit prüfen

De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?

Best practice & research. Clinical rheumatology, 2015-08, Vol.29 (4), p.550-565

2015

Link zum Volltext

Verfügbarkeit prüfen

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

Annals of the rheumatic diseases, 2013-11, Vol.72 (11), p.1800-1805

2013

Link zum Volltext

Verfügbarkeit prüfen

Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study

Rheumatology international, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study

Arthritis & rheumatology (Hoboken, N.J.), 2018-09, Vol.70 (9), p.1408-1418

2018

Link zum Volltext

Verfügbarkeit prüfen

Limited Diagnostic and Prognostic Value of Routine Radiographs in Newly Presenting Arthritis Suspected of Rheumatoid Arthritis: A Retrospective Study

Arthritis care & research (2010), 2024-04, Vol.76 (4), p.497-502

2024

Link zum Volltext

Verfügbarkeit prüfen

Disease activity-guided dose optimisation including discontinuation of TNF-inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study

Rheumatology (Oxford, England), 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)

Therapeutic advances in musculoskeletal disease, 2022-01, Vol.14, p.1759720X221142277-1759720X221142277

2022

Link zum Volltext

Verfügbarkeit prüfen

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort

BMC rheumatology, 2022-08, Vol.6 (1), p.45-45, Article 45

2022

Link zum Volltext

Verfügbarkeit prüfen

Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study

Rheumatology (Oxford, England), 2024-05, Vol.63 (5), p.1246-1250

2024

Link zum Volltext

Verfügbarkeit prüfen

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review

Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.301-308

2017

Link zum Volltext

Verfügbarkeit prüfen

Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors

Rheumatology (Oxford, England), 2024-01, Vol.63 (1), p.e1-e2

2024

Link zum Volltext

Verfügbarkeit prüfen

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis

Rheumatology (Oxford, England), 2022-06, Vol.61 (SI2), p.SI175-SI179

2022

Link zum Volltext

Verfügbarkeit prüfen

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Cochrane database of systematic reviews, 2019-05, Vol.5 (5), p.CD010455

2019

Link zum Volltext

Verfügbarkeit prüfen

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

BMJ (Online), 2015-04, Vol.350, p.h1389

2015

Link zum Volltext

Verfügbarkeit prüfen

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

Trials, 2022-04, Vol.23 (1), p.318-318, Article 318

2022

Link zum Volltext

Verfügbarkeit prüfen

Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis

PloS one, 2012-03, Vol.7 (3), p.e33199-e33199

2012

Link zum Volltext

Verfügbarkeit prüfen

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study

Rheumatology (Oxford, England), 2022-05, Vol.61 (6), p.2307-2315

2022

Link zum Volltext

Verfügbarkeit prüfen

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study

BMC musculoskeletal disorders, 2012-07, Vol.13 (1), p.117-117, Article 117

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(135)

Publikationsform

Artikel
(167)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(142)
Life Sciences & Biomedicine
(138)
Rheumatology
(118)
Humans
(110)
Rheumatoid Arthritis
(79)
Male
(66)
Female
(63)
Middle Aged
(59)
Arthritis, Rheumatoid - Drug Therapy
(54)
Aged
(44)
Adult
(36)
Treatment Outcome
(35)
Antirheumatic Agents - Therapeutic Use
(33)
Patients
(30)
Severity Of Illness Index
(28)
Arthritis
(23)
Cohort Studies
(23)
Antirheumatic Agents - Administration & Dosage
(22)
Antirheumatic Agents - Adverse Effects
(19)
Biological And Medical Sciences
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

Non‐Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study

i033 Biologic dose reduction: the physician's perspective

Genome‐wide Association Study of Methotrexate‐Induced Liver Injury in Rheumatoid Arthritis Patients

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study

De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study

Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study

Limited Diagnostic and Prognostic Value of Routine Radiographs in Newly Presenting Arthritis Suspected of Rheumatoid Arthritis: A Retrospective Study

Disease activity-guided dose optimisation including discontinuation of TNF-inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort

Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review

Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study

Suchergebnisse filtern